Literature DB >> 27665100

Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.

Akihiro Matsumoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27665100     DOI： 10.1007/s00535-016-1259-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  18 in total

1.  Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Yoko Sakamoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

2.  Hepatitis B reactivation after lamivudine.

Authors:  P Honkoop; R A de Man; R A Heijtink; S W Schalm
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

3.  Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.

Authors:  P Honkoop; R A de Man; H G Niesters; P E Zondervan; S W Schalm
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

4.  Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients.

Authors:  Feng Liu; Lei Wang; Xiao Ying Li; You De Liu; Jing Bo Wang; Zhao Hua Zhang; Yao Zong Wang
Journal:  J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 4.029

5.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

Authors:  Tetsuya Hosaka; Fumitaka Suzuki; Masahiro Kobayashi; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

7.  Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.

Authors:  Eiji Tanaka; Akihiro Matsumoto
Journal:  Hepatol Res       Date:  2013-05-07       Impact factor: 4.288

8.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

9.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.